SCHEMBL1102920

SCHEMBL1102920

Cc1c2ccccc2c(C)c2ncccc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.71
HSP90AA1 P07900 2/20 0.71
NPC1 O15118 1/20 0.71
CCR1 P32246 3/20 0.47
CCR8 P51685 3/20 0.47
HTT P42858 3/20 0.47
PSMD14 O00487 1/20 0.47
COPS5 Q92905 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC40A1 Q9NP59 1/20 0.43
CCR5 P51681 2/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
KDM4E B2RXH2 3/20 0.41
LMNA P02545 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
GMNN O75496 1/20 0.41
TP53 P04637 1/20 0.41
MMP2 P08253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2681389 0.86 L3MBTL1 (0.78) L3MBTL1HSP90AA1NPC1CCR1CCR8
SCHEMBL14224306 0.86 L3MBTL1 (0.78) L3MBTL1HSP90AA1NPC1CCR1CCR8
SCHEMBL28554365 0.84 L3MBTL1 (0.75) L3MBTL1HSP90AA1NPC1CCR1CCR8
SCHEMBL21297784 0.84 L3MBTL1 (0.68) L3MBTL1HSP90AA1NPC1CCR1CCR8
SCHEMBL15624642 0.84 L3MBTL1 (0.82) L3MBTL1HSP90AA1NPC1CCR1CCR8
SCHEMBL23482474 0.83 L3MBTL1 (0.58) L3MBTL1HSP90AA1NPC1CCR1CCR8
SCHEMBL250356 0.83 L3MBTL1 (1.00) L3MBTL1HSP90AA1NPC1CCR1CCR8
SCHEMBL21297755 0.83 HSP90AA1 (0.73) L3MBTL1HSP90AA1NPC1CCR1CCR8
SCHEMBL21297746 0.82 L3MBTL1 (0.71) L3MBTL1HSP90AA1NPC1CCR1CCR8
Water SCHEMBL10480837 0.81 L3MBTL1 (0.95) L3MBTL1HSP90AA1NPC1CCR1CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 L3MBTL1 1629/4885HSP90AA1 4884/4885NPC1 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.